PubRank

D G Poplack

Author PubWeight™ 161.08‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A 1987 5.65
2 Developmental hierarchy of immunoglobulin gene rearrangements in human leukemic pre-B-cells. Proc Natl Acad Sci U S A 1981 3.73
3 Immunoglobulin gene rearrangement and cell surface antigen expression in acute lymphocytic leukemias of T cell and B cell precursor origins. J Clin Invest 1983 2.91
4 Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system. J Infect Dis 1988 1.95
5 Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors. Cancer Res 1989 1.86
6 Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. Am J Med 1979 1.61
7 Abnormal CT scans of the brain in asymptomatic children with acute lymphocytic leukemia after prophylactic treatment of the central nervous system with radiation and intrathecal chemotherapy. N Engl J Med 1978 1.60
8 The cytotoxicity of thioguanine vs mercaptopurine in acute lymphoblastic leukemia. Leuk Res 1994 1.54
9 A rhesus monkey model for continuous infusion of drugs into cerebrospinal fluid. Lab Anim Sci 1990 1.44
10 Pyrimidine dideoxyribonucleosides: selectivity of penetration into cerebrospinal fluid. J Pharmacol Exp Ther 1988 1.43
11 Monocyte-mediated antibody-dependent cellular cytotoxicity: a clinical test of monocyte function. Blood 1976 1.40
12 Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N Engl J Med 1983 1.38
13 The effects of prophylactic treatment of the central nervous system on the intellectual functioning of children with acute lymphocytic leukemia. Am J Med 1981 1.38
14 Acute tumor lysis syndrome. A review of 37 patients with Burkitt's lymphoma. Am J Med 1980 1.36
15 L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res 1981 1.34
16 Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. J Clin Oncol 1987 1.34
17 The pharmacokinetics of zidovudine administered by continuous infusion in children. Ann Intern Med 1989 1.33
18 Pregnancy outcome following cancer chemotherapy. Am J Med 1980 1.30
19 Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 1996 1.27
20 The disposition and metabolism of 2',3'-dideoxycytidine, an in vitro inhibitor of human T-lymphotrophic virus type III infectivity, in mice and monkeys. Drug Metab Dispos 1988 1.26
21 Primate model for long-term study of intraventricularly or intrathecally administered drugs and intracranial pressure. Science 1977 1.15
22 Human T-cell antigen receptor (TCR) delta-chain locus and elements responsible for its deletion are within the TCR alpha-chain locus. Proc Natl Acad Sci U S A 1988 1.13
23 Lipid peroxidation in the killing of phagocytized pneumococci. Infect Immun 1974 1.13
24 Pharmacokinetics of zidovudine administered intravenously and orally in children with human immunodeficiency virus infection. J Pediatr 1989 1.12
25 Pharmacokinetics of subcutaneous methotrexate. J Clin Oncol 1988 1.11
26 Long-term neuropsychologic sequelae of childhood leukemia: correlation with CT brain scan abnormalities. J Pediatr 1985 1.11
27 Impact of nutrition on pharmacokinetics of anti-neoplastic agents. Int J Cancer Suppl 1998 1.04
28 Prophylaxis and treatment of leukemia in the central nervous system and other sanctuaries. Semin Oncol 1985 1.03
29 Adrenal suppression after short-term corticosteroid therapy. Lancet 1979 1.02
30 Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res 1993 1.01
31 Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. Clin Pharmacol Ther 1983 1.00
32 Bacteriological isolation garment. Lancet 1974 1.00
33 Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial. J Clin Oncol 1997 0.99
34 Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study. Clin Cancer Res 1998 0.99
35 Gene rearrangements as markers of clonal variation and minimal residual disease in acute lymphoblastic leukemia. J Clin Oncol 1987 0.99
36 Leukoencephalopathy and elevated levels of myelin basic protein in the cerebrospinal fluid of patients with acute lymphoblastic leukemia. N Engl J Med 1980 0.98
37 Central nervous system pharmacology of antileukemic drugs. Am J Pediatr Hematol Oncol 1989 0.98
38 The pharmacology of orally administered chemotherapy. A reappraisal. Cancer 1986 0.96
39 Central nervous system leukemia. Curr Opin Oncol 1996 0.95
40 Characterization of immunoglobulin and T-cell receptor gene patterns in B-cell precursor acute lymphoblastic leukemia of childhood. J Clin Oncol 1990 0.95
41 Intraventricular concentration times time (C x T) methotrexate and cytarabine for patients with recurrent meningeal leukemia and lymphoma. Cancer 1999 0.94
42 The effect of methotrexate on the bioavailability of oral 6-mercaptopurine. Clin Pharmacol Ther 1987 0.94
43 Computer assisted tomography in methotrexate encephalopathy. J Comput Assist Tomogr 1977 0.94
44 A primate model for study of methotrexate pharmacokinetics in the central nervous system. Cancer Res 1977 0.93
45 Cytosine arabinoside cerebrospinal fluid kinetics. Clin Pharmacol Ther 1984 0.93
46 Immunodeficiency in familial erythrophagocytic lymphohistiocytosis. Lancet 1978 0.93
47 Correlation of adenosine deaminase activity with cell surface markers in acute lymphoblastic leukemia. J Clin Invest 1978 0.92
48 Penetration of SCH-39304, a new antifungal triazole, into cerebrospinal fluid of primates. Antimicrob Agents Chemother 1990 0.92
49 Pharmacokinetics of all-trans-retinoic acid administered on an intermittent schedule. J Clin Oncol 1995 0.92
50 "Concentration x time" methotrexate via a subcutaneous reservoir: a less toxic regimen for intraventricular chemotherapy of central nervous system neoplasms. Blood 1978 0.92
51 Expression of interleukin-2 receptor beta subunit in hematopoietic malignancies. Blood 1989 0.92
52 T cell receptor alpha-, beta-, and gamma-genes in T cell and pre-B cell acute lymphoblastic leukemia. J Clin Invest 1987 0.92
53 Pharmacokinetics of PEG-L-asparaginase and plasma and cerebrospinal fluid L-asparagine concentrations in the rhesus monkey. Cancer Chemother Pharmacol 1993 0.92
54 Expression of the mdr-1/P-170 gene in patients with acute lymphoblastic leukemia. Blood 1989 0.91
55 Effect of body position on ventricular CSF methotrexate concentration following intralumbar administration. J Clin Oncol 1995 0.91
56 Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study. Blood 1998 0.91
57 Effect of continuous-infusion zidovudine therapy on neuropsychologic functioning in children with symptomatic human immunodeficiency virus infection. J Pediatr 1990 0.91
58 Current concepts. Biochemical markers in lymphoid malignancy. N Engl J Med 1980 0.90
59 Active transport of methotrexate from cerebrospinal fluid in humans. Cancer Res 1980 0.90
60 Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic leukemia. J Clin Invest 1992 0.90
61 Intrathecal administration of topotecan in nonhuman primates. Cancer Chemother Pharmacol 1995 0.90
62 Neoplastic meningitis: diagnosis and treatment considerations. Med Oncol 2000 0.90
63 Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. Cancer Res 1993 0.89
64 Quinolinic acid in the cerebrospinal fluid of children with symptomatic human immunodeficiency virus type 1 disease: relationships to clinical status and therapeutic response. J Infect Dis 1993 0.89
65 Pharmacokinetics and metabolism of cyclopentenyl cytosine in nonhuman primates. Cancer Res 1990 0.89
66 Pharmacokinetics of taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion. J Natl Cancer Inst 1994 0.88
67 Methotrexate distribution within the subarachnoid space after intraventricular and intravenous administration. Cancer Chemother Pharmacol 2000 0.88
68 Methotrexate levels in the interstitial space and seminiferous tubule of rat testis. Cancer Res 1982 0.88
69 Acute encephalopathy after initiation of cranial irradiation for meningeal leukaemia. Lancet 1978 0.87
70 Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers. J Clin Oncol 1998 0.87
71 The Ommaya reservoir: newly recognized complications and recommendations for insertion and use. Cancer 1978 0.87
72 Activation of leukemic pro-suppressor cells to become suppressor-effector cells. Influence of cooperating normal T cells. N Engl J Med 1981 0.87
73 Improved treatment results in the management of single and multiple relapses of acute lymphoblastic leukemia. Cancer 1980 0.87
74 Reduced pulsatile growth hormone secretion in children after therapy for acute lymphoblastic leukemia. J Pediatr 1984 0.86
75 ADCC against human erythrocyte target cells: role of the anti-target cell antibodies in determining lymphocyte killer activity. Clin Exp Immunol 1979 0.86
76 Pediatric phase I trial and pharmacokinetic study of piritrexim administered orally on a five-day schedule. Cancer Res 1990 0.86
77 Methotrexate pharmacokinetics following administration of recombinant carboxypeptidase-G2 in rhesus monkeys. J Clin Oncol 1992 0.86
78 High-performance liquid chromatographic method for analysis of 2',3'-dideoxyinosine in human body fluids. J Chromatogr 1990 0.86
79 The effect of Mycobacterium bovis (Bacillus Calmette-Guérin) on macrophage random migration, chemotaxis, and pinocytosis. Cancer Res 1976 0.86
80 Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer 1996 0.86
81 Ascending myelopathy after chemotherapy for central nervous system acute lymphoblastic leukemia: correlation with cerebrospinal fluid myelin basic protein. Med Pediatr Oncol 1985 0.86
82 Candida arthritis treated with amphotericin B. J Pediatr 1975 0.85
83 Dose-dependent pharmacokinetics of all-trans-retinoic acid. J Natl Cancer Inst 1992 0.85
84 Abnormal computed tomography brain scans in children with acute lymphoblastic leukemia: serial long-term follow-up. J Clin Oncol 1985 0.85
85 Acute lymphoblastic leukemia in childhood. Pediatr Clin North Am 1985 0.85
86 Effect of Corynebacterium parvum, methanol-extraction residue of BCG, and levamisole on macrophage random migration, chemotaxis, and pinocytosis. J Natl Cancer Inst 1977 0.84
87 Time course of induction of metabolism of all-trans-retinoic acid and the up-regulation of cellular retinoic acid-binding protein. Cancer Res 1993 0.84
88 Phase I study of 2'-deoxycoformycin in acute lymphoblastic leukemia. Cancer Res 1981 0.84
89 Remission induction of meningeal leukemia with high-dose intravenous methotrexate. J Clin Oncol 1985 0.84
90 Pharmacokinetics of intraventricular and intravenous N,N',N''-triethylenethiophosphoramide (thiotepa) in rhesus monkeys and humans. Cancer Res 1986 0.84
91 Variability in the oral bioavailability of all-trans-retinoic acid. J Natl Cancer Inst 1993 0.84
92 Leydig cell function in boys following treatment for testicular relapse of acute lymphoblastic leukemia. J Clin Oncol 1985 0.83
93 Current pharmacological treatment approaches to central nervous system leukaemia. Drugs 1991 0.83
94 Methotrexate-induced oral mucositis and salivary methotrexate concentrations. Cancer Chemother Pharmacol 1979 0.83
95 Testicular function in boys after chemotherapy for acute lymphoblastic leukemia. N Engl J Med 1981 0.83
96 Prolonged complete remission following high dose chemotherapy of Burkitt's lymphoma in relapse. Cancer 1978 0.83
97 Biochemical parameters of mercaptopurine activity in patients with acute lymphoblastic leukemia. Cancer Res 1986 0.82
98 Influence of food intake on bioavailability of oral 6-mercaptopurine in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol 1986 0.82
99 Intraventricular versus intralumbar methotrexate for central-nervous-system leukemia: prolonged remission with the Ommaya reservoir. Med Pediatr Oncol 1979 0.82
100 Bioavailability of oral trimetrexate in patients with acquired immunodeficiency syndrome. Antimicrob Agents Chemother 1988 0.82
101 Pharmacology of fludarabine phosphate after a phase I/II trial by a loading bolus and continuous infusion in pediatric patients. Cancer Res 1990 0.82
102 Plasma and cerebrospinal fluid pharmacokinetics of recombinant interferon alpha A in monkeys: comparison of intravenous, intramuscular, and intraventricular delivery. Cancer Drug Deliv 1985 0.82
103 Pharmacokinetics of subcutaneous azidothymidine in rhesus monkeys. Antimicrob Agents Chemother 1989 0.81
104 Stability of 5-fluorouracil in whole blood and plasma. Clin Chem 1987 0.81
105 Blindness during remission in two patients with acute lymphoblastic leukemia: a possible complication of multimodality therapy. Cancer 1977 0.81
106 Pediatric phase I trial, pharmacokinetic study, and limited sampling strategy for piritrexim administered on a low-dose, intermittent schedule. Cancer Res 1992 0.81
107 Pharmacokinetics of dideoxypurine nucleoside analogs in plasma and cerebrospinal fluid of rhesus monkeys. Antimicrob Agents Chemother 1995 0.81
108 Identification of 6-mercaptopurine riboside in patients receiving 6-mercaptopurine as a prolonged intravenous infusion. Biochem Pharmacol 1984 0.81
109 Intracranial and otological presentation of acute lymphocytic leukemia. Neurosurgery 1985 0.81
110 Characterization of lymphoblast Fc receptor expression in acute lymphoblastic leukemia. Blood 1979 0.80
111 Active clearance of corticotropin-releasing factor from the cerebrospinal fluid. Neuroendocrinology 1985 0.80
112 New cytotoxic drugs for intrathecal administration. J Neurooncol 1998 0.80
113 Diminished lymphoblast 5'-nucleotidase activity in acute lymphoblastic leukemia with T-cell characteristics. N Engl J Med 1979 0.80
114 Phase II study of 5-azacytidine in sarcomas of bone. Am J Clin Oncol 1982 0.80
115 Pharmacokinetic study of cerebrospinal fluid penetration of cis-diamminedichloroplatinum (II). Cancer Chemother Pharmacol 1981 0.80
116 Chronic ventricular cerebrospinal fluid sampling, drug injections, and pressure monitoring using subcutaneous reservoirs in monkeys. Neurosurgery 1978 0.80
117 Rescue of experimental intrathecal methotrexate overdose with carboxypeptidase-G2. J Clin Oncol 1991 0.80
118 Fc receptors on human T lymphocytes. V: Effects of colchicine and cytochalasin B on Fc receptor expression. J Immunol 1980 0.80
119 Combined modality treatment of Burkitt's lymphoma. Cancer Treat Rep 1978 0.80
120 Pharmacokinetics of trimetrexate (NSC 352122) in monkeys. Cancer Res 1986 0.80
121 Cerebrospinal fluid penetration of active metabolites of cyclophosphamide and ifosfamide in rhesus monkeys. Cancer Res 1988 0.79
122 Lactate dehydrogenase isoenzymes in normal and malignant human lymphoid cells. Blood 1982 0.79
123 Hypothalamic-pituitary dysfunction following CNS prophylaxis in acute lymphocytic leukemia: correlation with CT scan abnormalities. Med Pediatr Oncol 1979 0.79
124 An immunotoxin for the treatment of T-acute lymphoblastic leukemic meningitis: studies in rhesus monkeys. Cancer Immunol Immunother 1989 0.79
125 Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-beta-D-arabinofuranosylcytosine. Cancer Res 1982 0.79
126 The detection of Fc-IgA receptors on T and non-T, non-B acute leukemic lymphoblasts. Cell Immunol 1980 0.79
127 Neurotoxicities of current leukemia therapy. Am J Pediatr Hematol Oncol 1979 0.79
128 2'-beta-fluoro-2',3'-dideoxyadenosine, lodenosine, in rhesus monkeys: plasma and cerebrospinal fluid pharmacokinetics and urinary disposition. Drug Metab Dispos 1999 0.79
129 Transient acute hepatotoxicity of high-dose methotrexate therapy during childhood. NCI Monogr 1987 0.79
130 Subtle primary hypothyroidism in patients treated for acute lymphoblastic leukemia. Acta Endocrinol (Copenh) 1991 0.79
131 Lymphoblast purine pathway enzymes in B-cell acute lymphoblastic leukemia. Blood 1981 0.79
132 Kinetic model for disposition of 6-mercaptopurine in monkey plasma and cerebrospinal fluid. Am J Physiol 1985 0.78
133 High-performance liquid chromatographic method for the analysis of 2',3'-dideoxycytidine in human plasma. J Chromatogr 1990 0.78
134 Acceleration of myeloid recovery from cyclophosphamide-induced leukopenia by pretreatment with Bacillus Calmette-Guérin. Cancer Res 1978 0.78
135 Prolongation of drug exposure in cerebrospinal fluid by encapsulation into DepoFoam. Cancer Res 1993 0.78
136 Purine nucleoside phosphorylase activity in acute lymphoblastic leukemia. Blood 1980 0.78
137 Cerebrospinal fluid pharmacokinetics of intraventricular and intravenous aziridinylbenzoquinone. Cancer Res 1984 0.78
138 Misonidazole blood and cerebrospinal fluid kinetics in monkeys following intravenous and intrathecal administration. Eur J Cancer 1981 0.78
139 Stimulation of the beta-subunit of the IL-2 receptor induces MHC-unrestricted cytotoxicity in T acute lymphoblastic leukemia cells and normal thymocytes. J Immunol 1988 0.78
140 Inhibition of human lymphoproliferation by intravenous lipid emulsion. Clin Immunol Immunopathol 1982 0.78
141 Chronic myelomonocytic leukemia in childhood. Am J Hematol 1981 0.78
142 Transplantation of leukemic bone marrow treated with cytotoxic antileukemic antibodies and complement. Science 1982 0.78
143 Prevention of methotrexate cytotoxicity by asparaginase inhibition of methotrexate polyglutamate formation. Cancer Res 1985 0.77
144 Phase II trial of sequential methotrexate and 5-fluorouracil with leucovorin in children with sarcomas. Invest New Drugs 1990 0.77
145 Effect of intravenous dose and schedule on cerebrospinal fluid pharmacokinetics of 5-fluorouracil in the monkey. Cancer Res 1984 0.77
146 Sequential combination chemotherapy (containing high-dose cyclophosphamide) for metastic osteogenic sarcoma. Cancer Treat Rep 1978 0.77
147 Phase I trial and pharmacokinetic evaluation of fazarabine in children. Cancer Res 1989 0.77
148 Leukoencephalopathy following chemotherapy for rhabdomyosarcoma: reversibility of cerebral changes demonstrated by computed tomography. J Pediatr 1977 0.77
149 Cerebrospinal fluid and plasma pharmacokinetics of morphine infusions in pediatric cancer patients and rhesus monkeys. Pain 1987 0.77
150 Pharmacologic approaches to the treatment of meningeal malignancy. Oncology (Williston Park) 1991 0.77
151 A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer. Cancer Res 1995 0.77
152 Reversible dementia temporally associated with intraventricular therapy with methotrexate in a child with acute myelogenous leukemia. J Pediatr 1976 0.77
153 Delayed allergic reactions following intramuscular L-asparaginase. Med Pediatr Oncol 1980 0.76
154 Folate and methotrexate polyglutamate tissue levels in rhesus monkeys following chronic low-dose methotrexate. Cancer Drug Deliv 1987 0.76
155 Levels of 2'-deoxycoformycin, adenosine, and deoxyadenosine in patients with acute lymphoblastic leukemia. Cancer Res 1981 0.76
156 Pharmacokinetics of vincristine in the cerebrospinal fluid of subhuman primates. Cancer Res 1980 0.76
157 A pediatric phase I trial and pharmacokinetic study of thioguanine administered by continuous i.v. infusion. Clin Cancer Res 1997 0.76
158 The mononuclear phagocyte system: role in expression of immunocompetence in neonatal and adult life. Pediatrics 1979 0.76
159 Mechanism of resistance to cyclopentenyl cytosine (CPE-C) in Molt-4 lymphoblasts. Biochem Pharmacol 1993 0.76
160 Prolonged granulocytopenia from incompatible platelet transfusions. N Engl J Med 1974 0.76
161 Purine pathway enzyme abnormalities in acute lymphoblastic leukemia. Cancer Res 1981 0.76
162 Characterization of acute lymphoblastic leukemia of childhood by immunoglobulin and T-cell receptor gene patterns. Leukemia 1991 0.76
163 Cellular pharmacokinetics of mercaptopurine in human neoplastic cells and cell lines. Cancer Res 1985 0.76
164 Pharmacokinetics of mercaptopurine in children with acute lymphocytic leukemia. N Engl J Med 1990 0.76
165 Clinical pharmacology of 9-beta-D-arabinofuranosyladenine in combination with 2'-deoxycoformycin. Cancer Res 1982 0.76
166 Pharmacokinetics of pyrazoloacridine in the rhesus monkey. Cancer Res 1991 0.75
167 Intrathecal 6-mercaptopurine: preclinical pharmacology, phase I/II trial, and pharmacokinetic study. Cancer Res 1991 0.75
168 Retinoblastoma treatment. Science 1999 0.75
169 The effect of amitriptyline on the central nervous system penetration of methotrexate. Cancer Drug Deliv 1986 0.75
170 The child with recurrent solid tumor. Pediatr Clin North Am 1991 0.75
171 Preclinical pharmacology of arabinosyl-5-azacytidine in nonhuman primates. Cancer Res 1988 0.75
172 A phase II trial of continuous-infusion 6-mercaptopurine for childhood leukemia. Cancer Chemother Pharmacol 1992 0.75
173 Detection of double minute chromosomes in a child with acute lymphoblastic leukemia. Cancer Genet Cytogenet 1998 0.75
174 Advances in the treatment of meningeal cancers. Crit Rev Oncol Hematol 1995 0.75
175 Cerebrospinal fluid pharmacokinetics and toxicology of intraventricular and intrathecal arabinosyl-5-azacytosine (fazarabine, NSC 281272) in the nonhuman primate. Invest New Drugs 1994 0.75
176 Bacillus Calmette-Guérin enhancement of colony-stimulating activity and myeloid colony formation following administration of cyclophosphamide. Cancer Res 1979 0.75
177 Plasma and cerebrospinal fluid pharmacokinetics of acivicin in Ommaya reservoir-bearing rhesus monkeys. Cancer Treat Rep 1982 0.75
178 A phase II trial of continuous-infusion 6-mercaptopurine for childhood solid tumors. Cancer Chemother Pharmacol 1990 0.75
179 Heterogeneity of acute lymphocytic leukemia cell surface markers as detected by monoclonal antibodies. J Natl Cancer Inst 1983 0.75
180 Pharmacologic strategies for the treatment of meningeal malignancy. Invest New Drugs 1996 0.75
181 Meningeal relapse of orbital rhabdomyosarcoma. Med Pediatr Oncol 1978 0.75
182 Modulation of the cytotoxic effect of cyclopentenylcytosine by its primary metabolite, cyclopentenyluridine. Cancer Res 1992 0.75
183 Desulfuration of 6-mercaptopurine. The basis for the paradoxical cytotoxicity of thiopurines in cultured human leukemic cells. Biochem Pharmacol 1993 0.75
184 Mechanism of acquired resistance to methotrexate in P388 murine leukemia cells and in their doxorubicin-resistant subline. Isr J Med Sci 1989 0.75
185 Purine pathway enzymes in the circulating malignant cells of patients with cutaneous T-cell lymphoma. Br J Haematol 1982 0.75
186 A pediatric phase I and pharmacokinetic study of spirohydantoin mustard. Cancer Res 1988 0.75
187 Complications of leukemia. Pediatr Rev 1991 0.75
188 Ability of a new antitumor agent, AZQ, to penetrate into cerebrospinal fluid. Pharmacology 1981 0.75
189 Adverse prognostic influence of hepatitis B virus infection in acute lymphoblastic leukemia. Cancer 1986 0.75
190 Differentiation stages of childhood acute lymphoblastic leukemias with p53 mutations. Leukemia 1994 0.75
191 Pharmacokinetics of tiazofurin in the plasma and cerebrospinal fluid of rhesus monkeys. Cancer Res 1985 0.75
192 [Infectious complications from intraventricular route of administration in cancer patients]. Probl Med Wieku Rozwoj 1990 0.75
193 Pharmacokinetics of piroxantrone in a phase I trial of piroxantrone and granulocyte-colony stimulating factor. Cancer Res 1993 0.75
194 Clonal expansion of germline B-lineage acute lymphoblastic leukemia in severe combined immunodeficient mice. Oncogene 1995 0.75
195 Experimental approaches to the treatment of CNS leukemia. Am J Pediatr Hematol Oncol 1979 0.75
196 Hepatitis B virus infection in the Wiskott-Aldrich syndrome. J Pediatr 1976 0.75
197 Late soft tissue recurrence of acute lymphoblastic leukemia in a site of antecedent trauma. J Pediatr 1978 0.75
198 Acute lymphoblastic leukemia followed by chronic myelocytic leukemia. Blood 1978 0.75
199 Bioavailability of low-dose vs high-dose 6-mercaptopurine. Clin Pharmacol Ther 1988 0.75
200 Pharmacokinetics of 6-mercaptopurine (6MP) in the monkey. I. Disposition from plasma and cerebrospinal fluid following iv bolus. Drug Metab Dispos 1983 0.75
201 Treatment of acute lymphoblastic leukemia in relapse: efficacy of a four-drug reinduction regimen. Cancer Treat Rep 1981 0.75
202 Relationship of 5'-nucleotidase activity and antileukemic effect in 2'-deoxycoformycin therapy. Cancer Treat Rep 1982 0.75
203 Intrathecal 5-fluorouracil in the rhesus monkey. Cancer Chemother Pharmacol 1992 0.75
204 Probenecid inhibition of methotrexate cytotoxicity in mouse L1210 leukemia cells. Cancer Treat Rep 1984 0.75
205 Characterization of cross-resistance to methotrexate in a human breast cancer cell line selected for resistance to melphalan. Biochem Pharmacol 1995 0.75
206 Very high dose cyclophosphamide with imidazole carboximide and vincristine sulfate in the treatment of stage IV neuroblastoma. Am J Clin Oncol 1985 0.75
207 A rapid, single step technique for determination of B and T cell surface markers in malignant lymphoid cells. Exp Hematol 1982 0.75
208 Acute megakaryoblastic leukemia in childhood. Cancer 1984 0.75
209 Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. J Pediatr Hematol Oncol 1999 0.75
210 Cerebrospinal fluid levels of 2'-deoxycoformycin after systemic administration in monkeys. J Natl Cancer Inst 1982 0.75
211 Modulation of thiopurine cytotoxicity in the HL-60 cell line by physiological concentrations of hypoxanthine. Cancer Res 1986 0.75
212 Chronopharmacokinetics of oral methotrexate and 6-mercaptopurine: is there diurnal variation in the disposition of antileukemic therapy? Am J Pediatr Hematol Oncol 1989 0.75
213 Massive intrathecal overdose: "check the label twice!". N Engl J Med 1984 0.75
214 Antiretroviral drug development and clinical pharmacology. Pediatr Infect Dis J 1991 0.75
215 Pharmacology and drug resistance in childhood lymphoblastic leukemia. Hematol Oncol Clin North Am 1990 0.75
216 Altered phenytoin clearance during intensive chemotherapy for acute lymphoblastic leukemia. J Pediatr 1988 0.75
217 Pharmacokinetics, cerebrospinal fluid penetration, and metabolism of piroxantrone in the rhesus monkey. Invest New Drugs 1993 0.75
218 Phase I study of high-dose piroxantrone with granulocyte colony-stimulating factor. J Clin Oncol 1993 0.75
219 Pharmacokinetics of ICRF-187 in the cerebrospinal fluid of subhuman primates. Cancer Treat Rep 1981 0.75
220 Intrathecal administration of 4-hydroperoxycyclophosphamide in rhesus monkeys. Cancer Res 1987 0.75
221 Immunophenotypic analysis of acute lymphoblastic leukemia using routinely processed bone marrow specimens. Arch Pathol Lab Med 1991 0.75
222 Infectious complications of intraventricular reservoirs in cancer patients. Pediatr Infect Dis J 1987 0.75
223 A clinical trial of chemotherapy and RAJI immunotherapy in advanced acute lymphatic leukemia. Cancer Res 1975 0.75
224 The influence of route of administration on the hepatic uptake of methotrexate. Cancer Drug Deliv 1986 0.75
225 Development of chemotherapy treatment for pediatric brain tumors. Neurol Clin 1991 0.75